公开(公告)号：US20170107284A1

公开(公告)日：2017-04-20

申请号：US15363986

申请日：2016-11-29

申请人： Compugen Ltd

发明人： Amir TOPORIK ,  Amit NOVIK ,  Anat COHEN-DAYAG ,  Avi Yeshah ROSENBERG ,  Eve MONTIA ,  Galit ROTMAN ,  Liat DASSA ,  Merav BEIMAN ,  Ofer LEVY ,  Shira WALACH ,  Shirley SAMEACH- GREENWALD ,  Yaron KINAR ,  Zurit LEVINE ,  Gad S. COJOCARU ,  Sergey NEMZER

IPC分类号： C07K16/28 ,  G01N33/577 ,  G01N33/574 ,  C07K16/30 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K38/00 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/47 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3038 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/57484 ,  G01N33/577 ,  G01N2333/47

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of KRTCAP3, FAM26F, MGC52498, FAM70A and TMEM154 proteins and variants, and therapeutic usages thereof.

公开(公告)号：US20180298109A1

公开(公告)日：2018-10-18

申请号：US15882240

申请日：2018-01-29

申请人： Compugen Ltd.

发明人： Anat COHEN-DAYAG ,  Merav BEIMAN ,  Liat DASSA ,  Marina BUBIS ,  Shirley SAMEACH GREENWALD ,  Dalit LANDESMAN-MILO ,  Cynthia KOIFMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Tania PERGAM ,  Yaron KINAR ,  Zurit LEVINE ,  Avi ROSENBERG ,  Galit ROTMAN ,  Eve MONTIA ,  Amit NOVIK ,  Amir TOPORIK ,  Shira WALACH

IPC分类号： C07K16/30 ,  G01N33/574 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  A61K31/7088 ,  G01N33/564 ,  C07K16/28 ,  C07K14/82 ,  C07K14/705 ,  C07K14/47 ,  C07K14/00 ,  A61K38/00

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

公开(公告)号：US20140255411A1

公开(公告)日：2014-09-11

申请号：US13845420

申请日：2013-03-18

申请人： Compugen Ltd.

发明人： Zurit LEVINE ,  Amir TOPORIK ,  Amit NOVIK ,  Anat COHEN-DAYAG ,  Avi ROSENBERG ,  Cynthia KOIFMAN ,  Dalit LANDESMAN-MILO ,  Eve MONTIA ,  Galit ROTMAN ,  Liat DASSA ,  Marina BUBIS ,  Merav BEIMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Shira WALACH ,  Shirley SAMEACH- GREENWALD ,  Tania PERGAM ,  Yaron KINAR

IPC分类号： C07K16/30 ,  A61N5/10 ,  A61K39/39 ,  G01N33/574 ,  A61K47/48 ,  A61K39/395

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants a which are suitable targets for immunotherapy, cancer therapy, and drug development.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，C1ORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员，并且在包括肺癌，卵巢癌和结肠癌在内的癌症中差异表达， 诊断和治疗用途。 还提供了这些抗体用于调节B7共刺激和相关疗法（例如治疗自身免疫）的用途。 本发明还涉及发现VSIG1及其变体FXYD3及其变体ILDR1及其变体，LOC253012及其变体，AI216611及其变体和C1ORF32及其变体a的细胞外结构域，其是免疫治疗癌症的合适靶标 治疗和药物开发。

公开(公告)号：US20170037141A1

公开(公告)日：2017-02-09

申请号：US15011521

申请日：2016-01-30

申请人： Compugen Ltd.

发明人： Anat COHEN-DAYAG ,  Merav BEIMAN ,  Liat DASSA ,  Marina BUBIS ,  Shirley SAMEACH- GREENWALD ,  Dalit LANDESMAN-MILO ,  Cynthia KOIFMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Tania PERGAM ,  Yaron KINAR ,  Zurit LEVINE ,  Avi ROSENBERG ,  Galit ROTMAN ,  Eve MONTIA ,  Amit NOVIK ,  Amir TOPORIK ,  Shira WALACH

IPC分类号： C07K16/30 ,  A61K45/06 ,  A61K39/395

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，C1ORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员，并且在包括肺癌，卵巢癌和结肠癌在内的癌症中差异表达， 诊断和治疗用途。 还提供了这些抗体用于调节B7共刺激和相关疗法（例如治疗自身免疫）的用途。 本发明还涉及发现VSIG1及其变体FXYD3及其变体，ILDR1及其变体，LOC253012及其变体，AI216611及其变体和C1ORF32及其变体的细胞外结构域，其是免疫治疗，癌症治疗的合适靶标 ，药物开发。

公开(公告)号：US20160068606A1

公开(公告)日：2016-03-10

申请号：US14732537

申请日：2015-06-05

申请人： Compugen Ltd.

发明人： Amir TOPORIK ,  Amit NOVIK ,  Anat COHEN-DAYAG ,  Avi Yeshah ROSENBERG ,  Eve MONTIA ,  Galit ROTMAN ,  Liat DASSA ,  Merav BEIMAN ,  Ofer LEVY ,  Shira WALACH ,  Shirley SAMEACH- GREENWALD ,  Yaron KINAR ,  Zurit LEVINE ,  Gad S. COJOCARU ,  Sergey NEMZER

IPC分类号： C07K16/30 ,  C07K16/28 ,  A61K39/395

CPC分类号： C07K16/28 ,  A61K38/00 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/47 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3038 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/57484 ,  G01N33/577 ,  G01N2333/47

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of KRTCAP3, FAM26F, MGC52498, FAM70A and TMEM154 proteins and variants, and therapeutic usages thereof.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供针对在癌症中差异表达的KRTCAP3，FAM26F，MGC52498，FAM70A或TMEM154抗原以及诊断和治疗用途的治疗性抗体。 本发明还涉及KRTCAP3，FAM26F，MGC52498，FAM70A和TMEM154蛋白质和变体的细胞外结构域及其治疗用途。

公开(公告)号：US20140363446A1

公开(公告)日：2014-12-11

申请号：US14469546

申请日：2014-08-26

申请人： COMPUGEN LTD.

发明人： Amir TOPORIK ,  Amit NOVIK ,  Anat COHEN-DAYAG ,  Avi Yeshah ROSENBERG ,  Cynthia KOIFMAN ,  Dalit LANDESMAN-MILO ,  Eve MONTIA ,  Galit ROTMAN ,  Liat DASSA ,  Marina BUBIS ,  Merav BEIMAN ,  Ofer LEVI ,  Sergey NEMZER ,  Tania PERGAM ,  Yaron KINAR ,  Shirley SAMEACH- GREENWALD ,  Zurit LEVINE ,  Shira WALACH

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K14/47

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，C1ORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员，并且在包括肺癌，卵巢癌和结肠癌在内的癌症中差异表达， 诊断和治疗用途。 还提供了这些抗体用于调节B7共刺激和相关疗法（例如治疗自身免疫）的用途。 本发明还涉及发现VSIG1及其变体FXYD3及其变体，ILDR1及其变体，LOC253012及其变体，AI216611及其变体和C1ORF32及其变体的细胞外结构域，其是免疫治疗，癌症治疗的合适靶标 ，药物开发。

公开(公告)号：US20140255389A1

公开(公告)日：2014-09-11

申请号：US13904028

申请日：2013-05-29

申请人： Compugen Ltd.

发明人： Anat COHEN-DAYAG ,  Merav BEIMAN ,  Liat DASSA ,  Marina BUBIS ,  Shirley SAMEACH- GREENWALD ,  Dalit LANDESMAN-MILO ,  Cynthia KOIFMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Tania PERGAM ,  Yaron KINAR ,  Zurit LEVINE ,  Avi ROSENBERG ,  Galit ROTMAN ,  Eve MONTIA ,  Amit NOVIK ,  Amir TOPORIK ,  Shira WALACH

IPC分类号： C07K14/705 ,  A61K39/00 ,  G01N33/564 ,  A61K45/06 ,  G01N33/574 ,  C07K16/28 ,  A61K39/395

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，C1ORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员，并且在包括肺癌，卵巢癌和结肠癌在内的癌症中差异表达， 诊断和治疗用途。 还提供了这些抗体用于调节B7共刺激和相关疗法（例如治疗自身免疫）的用途。 本发明还涉及VSIG1及其变体FXYD3及其变体ILDR1及其变体，LOC253012及其变体，AI216611及其变体和作为免疫治疗，癌症治疗的合适靶标的C1ORF32及其变体的细胞外结构域的发现 ，药物开发。

公开(公告)号：US20140220011A1

公开(公告)日：2014-08-07

申请号：US13767891

申请日：2013-02-15

申请人： Compugen Ltd.

发明人： Amir TOPORIK ,  Amit NOVIK ,  Anat COHEN-DAYAG ,  Avi Yeshah ROSENBERG ,  Cynthia KOIFMAN ,  Dalit LANDESMAN-MILO ,  Eve MONTIA ,  Galit ROTMAN ,  Liat DASSA ,  Marina BUBIS ,  Merav BEIMAN ,  Ofer LEVY ,  Sergey NEMZER ,  Tania PERGAM ,  Yaron KINAR ,  Shirley SAMEACH-GREENWALD ,  Zurit LEVINE ,  Shira WALACH

IPC分类号： C07K14/00 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC分类号： C07K16/30 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0008 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  A61N5/10 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/82 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/60 ,  C07K2319/70 ,  G01N33/564 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2500/04

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, ClORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and ClORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，ClORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员，并且在包括肺癌，卵巢癌和结肠癌在内的癌症中差异表达， 诊断和治疗用途。 还提供了这些抗体用于调节B7共刺激和相关疗法（例如治疗自身免疫）的用途。 本发明还涉及VSIG1及其变体FXYD3及其变体ILDR1及其变体，LOC253012及其变体，AI216611及其变体以及作为免疫治疗，癌症治疗的合适靶标的ClORF32及其变体的细胞外结构域的发现 ，药物开发。